Pregnancy associated nasopharyngeal carcinoma: A retrospective case-control analysis of maternal survival outcomes
Creators
- 1. Department of Radiation Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University (Gastrointestinal and Anal Hospital of Sun Yat-sen University), Yuancun Er Heng Lu, Guangzhou, People's Republic of China. (China)
- 2. State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou (China)
- 3. State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou (China)
- 4. State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Department of Molecular Diagnostics, Cancer Center, Sun Yat-sen University, Guangzhou (China)
- 5. State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Department of Nasopharyngeal Cancer, Cancer Center, Sun Yat-sen University, Guangzhou (China)
- 6. State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Department of National Clinical Study Center for Anticancer Drugs, Cancer Center, Sun Yat-sen University, Guangzhou (China)
Description
Background: Pregnancy-associated nasopharyngeal carcinoma (PANPC) has been associated with poor survival. Recent advances in radiation technology and imaging techniques, and the introduction of chemotherapy have improved survival in nasopharyngeal carcinoma (NPC); however, it is not clear whether these changes have improved survival in PANPC. Therefore, the purpose of this study was to compare five-year maternal survival in patients with PANPC and non-pregnant patients with NPC. Methods: After adjusting for age, stage and chemotherapy mode, we conducted a retrospective case-control study among 36 non-metastatic PANPC patients and 36 non-pregnant NPC patients (control group) who were treated at our institution between 2000 and 2010. Results: The median age of both groups was 30 years (range, 23–35 years); median follow-up for all patients was 70 months. Locoregionally-advanced disease accounted for 83.3% of all patients with PANPC and 92.9% of patients who developed NPC during pregnancy. In both the PANPC and control groups, 31 patients (86.1%) received chemotherapy and all patients received definitive radiotherapy. The five-year rates for overall survival (70% vs. 78%, p = 0.72), distant metastasis-free survival (79% vs. 76%, p = 0.77), loco-regional relapse-free survival (97% vs. 91%, p = 0.69) and disease-free survival (69% vs. 74%, p = 0.98) were not significantly different between the PANPC and control groups. Multivariate analysis using a Cox proportional hazards model revealed that only N-classification was significantly associated with five-year OS. Conclusion: This study demonstrates that, in the modern treatment era, pregnancy itself may not negatively influence survival outcomes in patients with NPC; however, pregnancy may delay the diagnosis of NPC
Availability note (English)
Available from http://dx.doi.org/10.1016/j.radonc.2015.06.008Additional details
Identifiers
- DOI
- 10.1016/j.radonc.2015.06.008;
- PII
- S0167-8140(15)00290-X;
Publishing Information
- Journal Title
- Radiotherapy and Oncology
- Journal Volume
- 116
- Journal Issue
- 1
- Journal Page Range
- p. 125-130
- ISSN
- 0167-8140
- CODEN
- RAONDT
INIS
- Country of Publication
- Ireland
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47026563
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BIOMEDICAL RADIOGRAPHY; CARCINOMAS; CHEMOTHERAPY; DIAGNOSIS; METASTASES; MULTIVARIATE ANALYSIS; PATIENTS; PREGNANCY; RADIOTHERAPY
- Descriptors DEC
- DIAGNOSTIC TECHNIQUES; DISEASES; MATHEMATICS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; RADIOLOGY; STATISTICS; THERAPY
Optional Information
- Copyright
- Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.